Posted 1/20/2024, 11:49:00 AM
Pfizer and Moderna Face Slowing Demand for COVID Shots But Pipeline Offers Growth Potential
- COVID-19 vaccine demand has dropped significantly for Pfizer and Moderna, hurting revenue growth
- Pfizer is launching 19 new products to generate $20B in revenue by 2030, compensating for losses
- Moderna's RSV vaccine could return it to growth in 2025 and profitability in 2026
- Both companies have more potential new products in the pipeline beyond COVID-19 vaccines
- Pfizer offers dividends and value, but Wall Street expects higher upside potential for Moderna